Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: A novel mechanism of phenotypic heterogeneity in Creutzfeldt-Jakob disease

Fig. 2

Immunoblot and N-terminus epitope mapping of resPrPD from sCJDMV2 variants, sCJDMV1 and controls. a both resPrPD types 1 and 2 (arrows) from all MV variants reacted with the type-non-specific Ab 3F4. The three resPrPD major glycoform are present in all preparations. The unglycosylated components shows the ~ 21 kDa mobility of resPrPD type 1 in -MM1 and -MV1 (dotted arrow), and the 19 kDa mobility of resPrPD type 2 (solid arrow) in all other preparations. Both “pure” sCJDMV2K and the mixed variant MV2K-C (50:50%) exclusively display the 20 kDa band (dashed arrow) along with the 19 kDa type 2 component (solid arrow). b type 1-specific Ab 12B2, besides resPrPD type 1 of MM1 and MV1, also demonstrated all three glycoforms of the 20 kDa component in sCJDMV2K and MV2K-C (dashed arrow) confirming the type 1-like N-terminus immunoreactivity of the 20 kDa as well as of its other two glycoform components; note that unlike with 3F4, when probing with Ab 12B2 the “20” kDa band (dashed arrow) aligns with the unglycosylated isoform of MM1 and MV1 at 21 kDa. c Ab Tohoku-2, type 2-specific, reacted only with all resPrPD type 2 as indicated by the 19 kDa unglycosylated isoform (solid arrow). d SAF32 (to slightly more N-terminal epitopes than 12B2) recognizes resPrPD type 1 of MM1 and MV1 but not (or very weakly) resPrPD associated with MV2K and MV2K-C. All tissue samples were obtained from the frontal cortex. * Residue 97 (or another C-terminally closely adjacent N-terminus) is required for Tohoku-2 to immunoreact [17]

Back to article page
\